Within the discovery-to-market development cycle for biopharmaceuticals, cell line developent (CLD) plays a primary role in creating and selecting a cell line that becomes the Master Cell Bank (MCB) for clinical and commercial biomanufacturing.
However, CLD, primarily driven by resource-intensive manual cell culture processes and analytics, is often associated with long development timelines and large, complex data volumes. For every project, a wealth of data is generated. Consequently, cell culture scientists often face multiple issues when balancing essential outcomes, including their target protein's quality, stability, safety, potency, and yield. The need of the hour is a modular design framework that can leverage this data, unify processes, and transform current workflows in ways that will enable demands for shorter timelines and increasing complexity of modalities.